GlassScriptPhysician profile
Mary Sims
NPI 1790217099
$3,307.48
in general payments reported to CMS, 2019-2025
26 companies · $417 in 2025
The $417 reported for 2025 was more than what 76% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $262 · 2022: $957 · 2023: $945 · 2024: $727 · 2025: $417.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,088.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,088.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $448.23 | 2021-2025 | Injectafer |
| Abbvie INC. | $418.12 | 2021-2025 | Lo Loestrin Fe, Liletta, Qulipta |
| Mayne Pharma Commercial LLC | $365.24 | 2021-2025 | |
| Organon LLC | $234.35 | 2021-2025 | Nexplanon |
| Intuitive Surgical, INC. | $224.31 | 2022-2025 | |
| Exeltis, USA INC. | $211.96 | 2021-2025 | Slynd |
| Minerva Surgical, INC | $205.91 | 2023 | |
| Evofem Biosciences, INC. | $192.14 | 2021-2022 | |
| Shield Therapeutics INC | $144.39 | 2023-2024 | Accrufer |
| Terumo Medical Corporation | $135.67 | 2023 | Azur Cx Detachable |
| Astellas Pharma US INC | $109.73 | 2022-2024 | Veozah |
| Coopersurgical, INC. | $101.07 | 2022-2025 | Paragard T 380a |
| Biogen, INC. | $99.86 | 2024 | Zurzuvae |
| Mylan Pharmaceuticals INC. | $73.96 | 2021-2022 | |
| Amgen INC. | $58.61 | 2021-2025 | Evenity, Prolia, Prolia |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Therapeuticsmd, INC. | $45.01 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $44.79 | 2023 | Gemtesa, Myfembree |
| Medicem INC. | $36.51 | 2022-2023 | |
| Sage Therapeutics, LLC | $34.80 | 2024 | |
| Pfizer INC. | $32.56 | 2021-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $29.12 | 2025 | |
| Becton, Dickinson and Company | $19.38 | 2022 | |
| Merck Sharp & Dohme LLC | $14.30 | 2021 | |
| Currax Pharmaceuticals LLC | $14.09 | 2021 | |
| Avion Pharmaceuticals | $11.29 | 2021 | |
| Meditrina | $2.08 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Sims listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.